Theranostics Market Size Forecast: Revenue and CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Theranostics Industry By The Forecast Year 2029?

The theranostics market size has experienced rapid expansion in recent years. This market is projected to grow from $111.1 billion in 2024 to $122.98 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.7%. The expansion observed in the historic period can be attributed to advancements in molecular imaging, a shift to value-based healthcare, and integration in oncology.

The theranostics market size is projected to experience rapid growth in the coming years. It is forecast to reach $184.94 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 10.7%. The expansion observed during the forecast period can be ascribed to an increase in precision medicine initiatives, the broadening of applications beyond oncology, the aging population and the rise of chronic diseases, breakthroughs in biomarker discovery, and government support and funding. Key trends for the forecast period involve regulatory support, the development of companion diagnostics, an amplified focus on cancer theranostics, enhanced patient engagement and awareness, and technological convergence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

Which Major Market Drivers Are Shaping The Future Of The Theranostics Market?

The anticipated expansion of the theranostics market is linked to the increasing incidence of cancer. Cancer, characterized by unregulated cellular proliferation affecting multiple organs, is a major global cause of illness and death. Theranostics, which combines diagnostic and therapeutic approaches, shows considerable promise in managing cancer and long-term illnesses. This methodology allows for individualized and precise therapies through the merger of diagnostic and treatment functionalities, thereby fostering innovation within the healthcare sector. Consequently, the growing population of cancer patients will fuel the development of the theranostics market. For example, data from January 2022, provided by the National Cancer Institute (NCI), a United States government agency under the National Institutes of Health (NIH) focused on cancer research, prevention, and therapy, indicated that in the United States, roughly 5.4% of the populace, amounting to 18.1 million people, have survived cancer. Moreover, in 2022, there were 623,405 individuals diagnosed with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma, with this figure expected to increase to 693,452 by 2025. Hence, the increasing occurrence of cancer is a key factor propelling the theranostics market.

What Are The Emerging Segments Gaining Attention In The Theranostics Market?

The theranosticsmarket covered in this report is segmented –

1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases

2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies

3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users

Subsegments:

1) By Neurological Disorders: Alzheimer’s Disease; Parkinson’s Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders

2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases

3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders

4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases

5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases

Which Trends Are Impacting The Theranostics Market?

Leading companies within the theranostics market are prioritizing the creation of advanced technological solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by integrating diagnostics and therapeutics into a unified treatment approach. These trials are research studies that assess the combined application of diagnostic tests and targeted therapies to customize treatment strategies for individual patients. Their goal is to determine the effectiveness of specific treatments based on patient-specific biomarkers, thereby furthering personalized medicine. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, commenced the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Significant aspects of this trial include a rapid activation process facilitated by BAMF Health’s BAMF RapAct program, which allowed it to launch in just seven weeks, and an emphasis on using innovative radiopharmaceuticals that target the Gastrin-Releasing Peptide receptor (GRPR), aiming to expand treatment options for patients with limited therapeutic avenues.

Which Leading Players Are Enhancing Their Theranostics Market Presence Worldwide?

Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

What Are The Regional Market Dynamics Impacting The Theranostics Industry?

North America was the largest region in the global theranostics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Theranostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp

Browse Through More Reports Similar to the Global Theranostics Market 2025, By The Business Research Company

Tumor Ablation Therapy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

Negative Pressure Wound Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/negative-pressure-wound-therapy-global-market-report

Aromatherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795